FDA slams Spectrum and Oncopeptides cancer drugs over efficacy concerns ahead of ODAC meeting

[cafead]

via The FDA’s Oncologic Drugs Advisory Committee meeting on Thursday will likely be a slaughter for two biopharma companies, Spectrum Pharmaceuticals and Oncopeptides, as reviewers today raised significant concerns and questions for both sponsors in briefing documents released ahead of the meeting.

article source